NetScientific PLC PDS Phase 2 Clinical Trial Update
05 Outubro 2021 - 3:00AM
RNS Non-Regulatory
TIDMNSCI
NetScientific PLC
05 October 2021
NetScientific plc
("NetScientific", the "Group" or the "Company")
PDS Phase 2 Clinical Trial Update
PDS Biotech Enrolls First Stage of Checkpoint Inhibitor Naïve
Patient Arm of Phase 2 Clinical Trial in Advanced HPV-16 Positive
Head and Neck Cancer
London, UK - 05 October 2021 - NetScientific plc (AIM: NSCI),
the international life sciences and sustainability technology
investment and commercialisation Group, announces that its
portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB),
has announced the completion of enrollment for the first stage of
the checkpoint inhibitor naïve arm of its VERSATILE-002 Phase 2
study for the treatment of recurrent and/or metastatic human
papillomavirus (HPV16)-associated head and neck cancer. 90% of
HPV-associated head and neck cancers are reported to be caused by
HPV16 as reported by a study published in the Journal of Clinical
Medicine.
VERSATILE-002 is studying two groups of HPV16-positive head and
neck cancer patients whose cancer has returned or spread. The first
group has not been previously treated with a checkpoint inhibitor
(CPI naïve). The second group of patients have failed multiple
treatments including checkpoint inhibitor therapy (CPI refractory).
As specified in the clinical trial design, objective response is
measured by radiographic tumor responses according to RECIST 1.1
(tumor reduction of 30% or more). If objective response is achieved
among at least four of the first 17 patients in the CPI naïve arm,
this will trigger advancement to the second stage of the study arm
and enrollment of the planned 54 patients in the CPI naïve arm. The
trial is being conducted in collaboration with Merck & Co.
Dr. Lauren V. Wood, Chief Medical Officer of PDS Biotech
"Completion of enrollment among checkpoint inhibitor naïve patients
in this first stage of our VERSATILE-002 Phase 2 study in the CPI
naïve arm is an important milestone, and we would like to thank the
patients for their participation in this clinical trial.
"Through their involvement, together with site Investigators and
study staff, this trial will help us better understand the
potential contribution that PDS0101 may have in improving the lives
of patients with advanced head and neck cancer."
Ilian Iliev, CEO of NetScientific, commented: "We are delighted
with the progress PDS is continuing to make with this Phase 2
clinical trial in collaboration with Merck & Co. This follows
the positive preliminary results from the NCI-led Phase 2 trials
announced in June this year."
NetScientific's interest in PDS amounts to c. 4.72 per cent.
The full text of the announcement from PDS Biotechnology is
available online here:
https://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/113-2021-news/564-iotechnrollsirsttageofheckpointnhibitora20211004
For more information, please contact:
NetScientific Via Walbrook PR
Ilian Iliev, CEO
WH Ireland (NOMAD, Financial Adviser
and Broker)
Chris Fielding / Darshan Patel +44 (0)20 7220 1666
Walbrook PR
Nick Rome/ Paul McManus/ 07748 325 236, 07980 541 893
Nicholas Johnson or 07884 664 686
About NetScientific
NetScientific plc (AIM: NSCI) is a holding company, that invests
in, develops, commercialises and realises shareholder value in life
sciences/healthcare, sustainability and technology companies, which
offer significant growth potential predominately in the UK and USA,
as well as globally.
With the acquisition of EMV Capital in August 2020, the Group
doubled its portfolio from 8 to 17 companies, either through direct
subsidiary, balance sheet investment or capital under advisory,
varying from start-up private companies to publicly listed
equities.
NetScientific delivers shareholder returns through a proactive
and hands-on management approach to their portfolio companies;
identifying, investing in, and helping to build game-changing
companies. The Group targets value inflection points and the
release of value through partial or full exits from trade sales,
public listings, or equity sales. The Company has a strong
transatlantic and growing international presence, providing
attractive expansion prospects.
NSCI can deploy a capital-light investment structure; utilising
the power of the PLC Brand, and the NetScientific balance sheet to
anchor future investments and achieve a multiplier effect by
attracting 3rd party investment for the portfolio companies.
NetScientific is headquartered in London, United Kingdom, and
was admitted to trading on AIM, a market operated by the London
Stock Exchange, in 2013 (website: www.netscientific.net ).
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAMIBLTMTBMBMB
(END) Dow Jones Newswires
October 05, 2021 02:00 ET (06:00 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024